The present invention relates to a pharmaceutical composition containing .alpha.-lipoic acid (LA) as an active ingredient. .alpha.-lipoic acid is an inhibitor of fractalkine expression, and exhibits effects of alleviating inflammation due to endotoxemia by decreasing expression of fractalkine and attachment of endothelial cells to monocytes in endothelial cells of an LPS-induced endotoxemia model.